Concepedia

Paul Bamborough

PB

69

Publications

5.5K

Citations

38

H-Index

1993

Active since

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (Germany)

GlaxoSmithKline (United States)

Molecular Discovery (United Kingdom)

University of Strathclyde

Paul Bamborough is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

ORCID

Top concepts

Publications per year

1993–2022

69

Publications

69

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Omer Gilan, Inmaculada Rioja, Kathy Knezevic et al. · Science · 2020 · 411 citations · Full text

Comprehensive characterization of the Published Kinase Inhibitor Set

Jonathan M. Elkins, Vita Fedele, M. Szklarz et al. · Nature Biotechnology · 2015 · 338 citations · Full text

Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains

Chun‐wa Chung, Hervé Coste, Julia H. White et al. · Journal of Medicinal Chemistry · 2011 · 334 citations · Full text

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Olivier Mirguet, Romain Gosmini, Jérôme Toum et al. · Journal of Medicinal Chemistry · 2013 · 301 citations · Full text

, , +22

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition

Natalie H. Theodoulou, Paul Bamborough, Andrew J. Bannister et al. · Journal of Medicinal Chemistry · 2015 · 229 citations · Full text

, , +14

Rows per page

1–5 of 69